Jerald Radich, MD
Medical Oncology · Seattle, WANPI 1134339591
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $67,216 of the $82,940 with a category attached, or 81.0%. 15 manufacturers reported payments, led by Novartis at 47.5% of the total. Reporting peaked in 2019 at $43,680 and has fallen 93.7% since, to $2,760 in 2025.
Across 58 payments — averaging $1430.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$39K
- Takeda Pharmaceuticals U.S.A., Inc.$10K
- Cepheid$9K
- Amgen$6K
- Bio-rad Laboratories, Inc.$5K
- E.r. Squibb & Sons, L.L.C.$5K
- plus $9K from 9 others
Across 24 payments — averaging $23,572 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$318K
- AstraZeneca$188K
- Cepheid$55K
- Bio-rad Laboratories, Inc.$5K
What the payments were for
- Consulting fees$67,21681%
- Speaking & faculty fees$10,54313%
- Travel & lodging$4,0805%
- Food & beverage$1,1021%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 21 | $39,378 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $9,933 |
| Cepheid | 7 | $9,191 |
| Amgen | 2 | $5,698 |
| Bio-rad Laboratories, Inc. | 2 | $4,916 |
| E.r. Squibb & Sons, L.L.C. | 8 | $4,773 |
| Janssen Research & Development, LLC | 1 | $2,860 |
| Bristol Myers Squibb | 1 | $1,978 |
| Daiichi Sankyo Inc. | 1 | $1,875 |
| Genentech USA, Inc. | 2 | $1,361 |
| Novartis Pharma AG | 1 | $655 |
| Pfizer | 1 | $135 |
| Sanofi | 1 | $104 |
| AstraZeneca | 1 | $47 |
| Taiho Oncology, Inc. | 2 | $36 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$82,940 in reported general payments places this provider in the 85th percentile of 162 medical oncology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Seattle
- Bart ScottSeattle$1.3M
- Petros GrivasSeattle$628K
- Vijayakrishna GadiSeattle$573K
- Evan YuSeattle$296K
- Siddhartha DevarakondaSeattle$215K
- David MaloneySeattle$150K
- Gary LymanSeattle$130K
- Rafic FarahSeattle$114K
- Laura ChowSeattle$114K
- Shailender BhatiaSeattle$107K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.